BPIQ Blog

Apr 29, 20195 min read

FDA Decision on Heron's Non-Opioid Pain Med Imminent

We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011....

Apr 8, 201910 min read

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

BIopharma companies (Concert and Incyte) patent dispute.

Apr 8, 20197 min read

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

(For a longer version of this article, with more detailed legal facts, please CLICK HERE.) Concert (CNCE) and Incyte (INCY) have been...

Apr 2, 20192 min read

SGMO Shows Early Progress in Gene Therapy and Ex-Vivo Programs

Sangamo (SGMO) provided an update today on its clinical programs, with its first clinical data for its Phase I Hemophilia A (gene...

Mar 12, 20191 min read

HRTX Opioid-Free Pain Med Candidate Continues to Impress

Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest...

Jump start your biotech due diligence

Our platform helps you uncover your next biotech investment opportunity